Summary It is almost 50 years since antimetabolites were first found to have clinical antitumour activity, with Farber's discovery that aminopterin could cause remission in acute leukaemia. In the following 10 years, methotrexate, 6-mercaptopurine and 5-fluorouracil (5-FU) found their way into clinical practice. Subsequently, cytosine arabinoside was found to have activity in acute leukaemia, but, until recently, other significant developments have involved optimizing the efficacy of existing antimetabolites, including the use of leucovorin with methotrexate or 5-FU. Recently, new antimetabolites have become a fertile area for anti-cancer drug research. Gemcitabine (GEMZAR®) has emerged as an important new agent in several tumour types, including pancreatic, non-small-cell lung, bladder, breast and ovarian cancers. Capecitabine is an intriguing new prodrug, offering tumour selectivity and prolonged tumour exposure to 5-FU. More potent thymidylate synthase inhibitors have also emerged; raltitrexed is now commercially available for the treatment of colorectal cancer. Others under development include LY231514, which has other sites of action, hence the acronym MTA (multi-targeted antifolate). A novel target is glycinamide ribonucleotide formyltransferase (GARFT) and LY309887 and AG2034 are undergoing clinical investigation as GARFT inhibitors. A critical element with LY309887 appears to be co-administration of folate. It seems entirely possible that several novel antimetabolites will establish themselves in clinical practice in future for the treatment of solid tumours.
Antimetabolites have been in use for the treatment of malignant disease for 50 years, since the discovery by Farber that aminopterin could cause remission of leukaemia (Farber et al, 1948) . Since then, antimetabolites have been discovered that have found use in a variety of diseases other than cancer. For example, methotrexate is used in the treatment of psoriasis (McDonald, 1981) and rheumatoid arthritis (Hoffmeister, 1983) , whereas trimetrexate has been used to treat Pneumocystis carinii infections in patients with acquired immune deficiency syndrome (Allegra et al, 1987a) . But cancer therapy is their main application and for many years, 5-fluorouracil (5-FU) and methotrexate have been the mainstay of antimetabolite treatment in solid tumours. In recent years, however, several new antimetabolites have emerged in cancer treatment and these have provided the basis for further research.
An antimetabolite is defined as a drug that interferes with the normal metabolic processes within cells. Knowledge of these processes at a cellular level has increased in recent years, leading to the identification of a number of potential new targets. The metabolic processes of the cell are complex and involve many enzymes. Two important pathways exist, which give rise to the synthesis of purines and pyrimidines. Folate-derived co-factors are also involved in these processes as the one-carbon fragments provided by folates are essential to certain transformations, such as the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Inhibitors of vital enzymes in these pathways are being studied, including dihydrofolate reductase (DHFR), Correspondence to: SB Kaye thymidylate synthase (TS), and glycinamide ribonucleotide formyltransferase (GARFI'). These are illustrated in Figure 1 , and will be discussed later. Other pharmacological targets have included the transport mechanisms responsible for ensuring drug uptake by the cell and, to this end, drugs have been developed that are better substrates for the reduced folate carrier (RFC) and the membraneassociated folate-binding protein (mFBP). These too will be discussed, along with compounds that have been designed to bypass these transport mechanisms. Nucleoside analogues, which play their role after incorporation into DNA and RNA, giving rise to chain termination and cell death or stasis, are among the most widely used of antimetabolites and will be reviewed in some detail. However, a full and complete discussion of every antimetabolite known would be beyond the scope of this review; therefore, only those examples that are of greatest interest will be discussed.
POTENTIAL TARGETS FOR CHEMOTHERAPEUTIC INTERVENTION Dihydrofolate reductase inhibitors
Methotrexate (Figure 2) , one of the earliest antimetabolites discovered, has been in use in cancer chemotherapy for over 30 years (Jolivet et al, 1983) . It is an inhibitor of DHFR, which occupies a central position in the metabolic pathway. DHFR is responsible for the conversion of dihydrofolate to tetrahydrofolate and ultimately to 10-formyl tetrahydrofolate. The last compound provides the formyl group for glycinamide ribonucleotide formyltransferase (GARFT) and aminoimidazole carboxamide ribonucleotide formyl transferase (AICARFT). Thus, the inhibition of DHFR results in depletion of intracellular pools of reduced folates and ultimately in reduced synthesis of purines and pyrimidines. The predominant mechanism of action of methotrexate is uncertain, as polyglutamated forms of the drug also inhibit TS and AICARFT (Allegra et al, 1987b) .
Resistance to methotrexate arises by a variety of mechanisms, including impaired transport via the reduced folate carrier (Gorlick et al, 1996) . This has inspired the search for other DHFR inhibitors, and led to the discovery of several methotrexate analogues including trimetrexate (Marshall and Delap, 1994) and edatrexate (Sirotnak et al, 1984) . Trimetrexate is more lipophilic than methotrexate and is not dependent on the RFC for entry into the cell. This leads to higher concentrations of trimetrexate within the cell, although the drug does not undergo polyglutamylation. Clinical trials with trimetrexate are continuing; as yet there is no convincing evidence of superiority over methotrexate. Another DHFR inhibitor that has shown activity in humans is piritrexim. This is another compound that does not rely on the RFC, but enters the cell by means of passive diffusion. It has oral bioavailability of 75%, and clinical schedules with repeated low doses have been developed because of a relatively short half-life (3-5 h) (Feun et al, 1991) . Activity has been seen for this drug in phase II trials in urothelial and head and neck tumours, as well as in melanoma, and evaluation is continuing.
Side-effects seen with this class of drug, as with most antimetabolites, consist mainly of toxicity to rapidly dividing cells, therefore mucositis, myelosuppression and thrombocytopenia are common. These effects are usually reversible and chemotherapy can be continued once levels have returned to normal. It has been known for several years that co-administration of leucovorin can reduce these toxicities to acceptable levels (Pinedo et al, 1976) . Folic acid antagonists in general are embryotoxic and have caused spontaneous abortion in animals (Hausknecht, 1995) .
Nucleoside analogues
Another drug which has been in use for several decades is 5-fluorouracil (5-FU, Figure 3 ) (Moertel, 1978) . It is a fluoropyrimidine, and is a member of the class of agents known as nucleoside analogues (Figure 3 ). In general, these agents function by replacing nucleosides in one or more normal cell functions because of their similarity to the naturally occurring substrates. They may fall into one of two main classes, either being incorporated into DNA and RNA synthesis or being responsible for inhibition of one of the enzymes essential to cell metabolism. The precise mechanism of action of 5-FU is unclear, and is partly a function of dose and schedule. However, it is likely that thymidylate synthase is the main target for the nucleoside of 5-FU, which binds to the active site of the enzyme in a similar manner to dUMP. This is followed by incorporation of the folate co-factor (Pestalozzi et al, 1997) , gastric cancer (Lenz et al, 1995) and primary rectal cancer (Johnston et al, 1994) all reach similar conclusions, with TS expression being measured either immunohistochemically, or using PCR to measure genetic expression of TS mRNA.
Second, correlations have also been drawn with response to 5-FU-based chemotherapy, in these and other studies. In studies in gastric cancer (Lenz et al, 1995) and in head and neck cancer , 65 and 70 patients, respectively, received 5-FU-based neoadjuvant chemotherapy, and in both cases there was a significant (P < 0.001, P = 0.02, respectively) inverse correlation between TS expression level and response. A similar conclusion was drawn in a smaller study of 22 patients with advanced colorectal cancer (Leichman et al, 1995) , in which a significant association (P = 0.004) between high TS expression and lack of response to infusional 5-FU was noted.
Conversely, in those studies that have attempted to correlate TS expression level with outcome of adjuvant chemotherapy; the opposite has been seen, i.e. patients with high TS levels have a better outcome with that therapy. This has been seen both in 278 node-positive breast cancer patients receiving CMF (cyclophosphamide, methotrexate, 5-FU) (Pestalozzi et al, 1997) and in 194 patients with Dukes' B and C rectal cancer receiving MOF (methyl CCNU, 5-FU vincristine) chemotherapy (Johnston et al, 1994) . The reasons for the apparent paradox are not clear, but the data reported to date would certainly justify further translational studies to clarify the predictive role of TS expression; it remains quite possible that this will vary according to the type of tumour being treated.
Other recently developed nucleoside analogues include the 5-FU prodrug capecitabine (Figure 3) (Miwa et al, 1990 ). This cytidine analogue is administered as an oral formulation and passes unchanged through the intestinal mucosa. It is activated through a series of enzymatic steps in the liver and in tumour cells, with conversion to 5-FU in a potentially tumour-selective manner by the enzyme thymidine phosphorylase. Phase I studies of oral therapy with capecitabine in adult patients with a variety of advanced and/or metastatic solid cancers have shown that the drug is well tolerated (Hughes et al, 1996) . Dose-limiting toxicities (DLT) included nausea, mucositis, diarrhoea and neutropenia. Palmar-plantar dyserythrodysthesia has also been seen. Pharmacological data indicate that to an extent, capecitabine simulates an i.v. protracted infusion of 5-FU; there is also clinical evidence of selective uptake in tumour biopsies after drug administration (Schuller et al, 1997) . Evidence of response was seen in a variety of tumours, including breast, colorectal and oesophageal cancers, and occurred over a wide range of doses. Phase II trials have confirmed activity in breast and colorectal cancer, and randomized phase III studies are in progress.
Deoxynucleoside analogues are also finding an expanding application in cancer chemotherapy. The first of these agents was cytosine arabinoside (cytarabine). This is commonly used in the treatment of acute myeloblastic leukaemia (Keating et al, 1982) but has no significant action in solid tumours. After activation to the triphosphate, cytarabine has a range of modes of action, including incorporation into DNA and subsequent chain termination, stimulation of apoptosis and inhibition of DNA polymerase. Side-effects of treatment with cytarabine can include pancytopenia, alopecia, nausea, vomiting, fever, myalgia and bone and chest pain, and the drug is clearly schedule dependent in terms of toxicity and efficacy.
Analogues of cytarabine have been developed more recently, with broader spectrum anti-tumour activity. The first is gemcitabine, a difluorinated analogue (Hertel et al, 1988) . Its activity is dependent upon the formation of a mononucleotide that is subsequently incorporated into DNA (Huang et al, 1991) . One more residue is incorporated into the chain before chain termination takes place. This mechanism, termed 'masked chain termination', makes the recognition and excision of the modified DNA very difficult, and may partly explain the drug's broad activity. In addition, gemcitabine is capable of 'self-potentiation', whereby accumulation of the active metabolite leads to increased efficacy through reduction of intracellular pools of dCTP, after inhibition of ribonucleotide reductase, deoxycytidine deaminase, DNA polymerase and CTP synthetase.
Clinical trials have been carried out to investigate the effect of schedule on the anti-tumour activity of gemcitabine, with the result that a weekly schedule was identified as having maximum potential (Abbruzzese et al, 1991) . Preclinical studies have indicated that, unlike cytarabine, gemcitabine had a high level of activity in solid tumours, and this has been borne out in clinical trials. Activity has been seen for this agent in a variety of tumours, including pancreas, ovary, bladder, breast and lung cancers (Kaye, 1994; Abratt et al, 1995; Anderson et al, 1995; Carmichael et al, 1995; Burris et al, 1997) . Improvements have been seen in the quality of life of patients with pancreatic cancer and other trials have investigated the effect of gemcitabine in combination therapy, for example with cisplatin in the treatment of NSCLC (Steward, 1997) .
Other agents in this class include ethynyl uracil (Porter et al, 1992) , decitabine (Richel et al, 1988 ) and the fludarabine analogue cladribine (Kay et al, 1992) , all of which are currently under clinical investigation. Figure 4) has been the subject of intense research activity in recent years (Takemura and Jackman, 1997) . Thymidylate synthase is essential to the synthesis of deoxythymidine monophosphate (dTMP) from deoxyuridine monophosphate (dUMP). This process is the sole source of dTMP in the cell and its inhibition leads to the depletion of cellular thymidine. CB3717 was the first quinazoline TS inhibitor to undergo preclinical and clinical investigation. The compound was found to have excellent in vitro and in vivo anti-tumour activity (Jones et al, 1981) . It enters the cell by means of the reduced folate carrier and requires polyglutamation for its activity. In phase I studies, responses were noted in lung and breast cancers, although renal toxicity was seen to be unpredictable and severe (Sessa et al, 1988) . Subsequent phase II trials confirmed this and the development of the drug was discontinued (Cantwell et al, 1988) . ZD1694 (raltitrexed) is a water-soluble analogue of CB3717 that was developed with the aim of reducing the side-effects seen in the parent compound (Kelland et al, 1992) . This appeared to be successful, in that the renal toxicity observed with CB3717 was absent in raltitrexed, whereas the anti-tumour activity was retained. Clinical trials have confirmed the activity of raltitrexed in several tumour types, including breast and colorectal cancers (Zalcberg et al, 1996; Smith et al, 1994) . Side-effects include neutropenia, transient elevations in transaminase levels, and gastrointestinal disturbances. Randomized trials in colorectal cancer have confirmed the activity of raltitrexed in comparison to standard 5-FU schedules, although the level of activity has been variable between studies (Pazdur and Vincent, 1997; Zalczberg, 1997) . Raltitrexed was approved in the UK in March 1996 for use in the treatment of colorectal cancer.
A potential successor to raltitrexed is ZD933 1. It, too, is a water-soluble compound but is not a substrate for folylpolyglutamyl synthetase (FPGS); hence it may overcome resistance to conventional polyglutamated TS inhibitors that may be due to defective FPGS activity (Stephens et al, 1994) . Preclinical studies have shown impressive in vivo activity against human tumour xenografts, as well as activity in raltitrexed-resistant cell lines (Jackman et al, 1995) . Phase I clinical trials with this compound are now underway. In recent years, medicinal chemists have used computer-aided molecular design for the development of new and more potent TS inhibitors. One example that has undergone extensive testing is AG337 (Thymitaq) (Webber et al, 1993) . The compound is lipophilic and requires neither the RFC nor FPGS for activity, entering the cell by passive diffusion. Preclinical studies have shown activity in a range of human xenografts, though this is clearly schedule dependent (Webber et al, 1996) . Phase I studies with AG337 have been conducted with a range of oral and i.v.
schedules. Toxicities seen include nausea, myelosuppression and mucositis. Activity has been seen in head and neck cancer, pancreatic cancer and hepatoma (Clendininn and Johnston, 1996) , and randomized trials, using a protracted i.v. infusion of AG337, are underway. MTA is a novel pyrrolo-pyrimidine antifolate (Taylor and Kuh, 1992) with early evidence of clinical activity ( Figure 5 ). Its major mechanism of activity is through the inhibition of TS, but it is also known to inhibit DHFR and GARFT, and hence has become known as a multitargeted antifolate, MTA (Shih et al, 1997) . Once MTA has entered the cell, it undergoes polyglutamation that results in prolonged intracellular retention and enhanced inhibition of TS and GARFT. Anti-tumour activity has been demonstrated in mouse leukaemia and colorectal cancer models (Schultz et al, 1996) . Three schedules were explored in the phase I setting, including weekly times 4 every 6 weeks (Rinaldi et al, 1995) , once every 3 weeks (Rinaldi et al, 1996) and daily times 5 every 3 weeks (McDonald et al, 1996 (Ray et al, 1993) . Early preclinical data suggested that co-administration of folic acid could reduce toxicity (Mendelsohn et al, 1996a) , and these observations have been borne out in the clinic (Ray et al, 1993; Laohavinj et al, 1996) . Clinical development of lometrexol was not continued after phase I studies because of the development of a more potent compound, LY309887. Preclinical studies demonstrated activity in a broad spectrum of tumours, including 6C3HED lymphosarcoma, C3H mammary tumours C3H mice, LX-1 lung and HC 1 colon human xenografts in nude mice (Mendelsohn et al, 1996b) . Phase I studies are ongoing to address the critical questions of an appropriate schedule, and the dose and duration of folic acid supplementation. Drug design through computer modelling has also been used in this field, and three compounds are now in development. These are AG2032 and AG2034 , both GARFT inhibitors, and AG2009, an inhibitor of AICARFT (Faessel et al, 1996) . Activity has been demonstrated for AG2034 against a range of human tumour xenografts , and clinical trials are underway using a range of schedules.
CONCLUSION
There has clearly been a resurgence in the field of antimetabolite therapy. Information on cellular metabolism, in particular identification of the important enzymes involved, has provided new British Journal of Cancer (1998) 6 SB Kaye targets for chemotherapeutic intervention. There is no doubt that the development of new nucleosides will have a significant impact on anti-cancer treatment in the future, as will the new generation of TS inhibitors. The activity of these classes of drug against solid tumours previously considered to be refractory to antimetabolite therapy is particularly noteworthy.
Ultimately, the place for many of these drugs may be in combination therapy, in which novel mechanisms of action and improved side-effect profiles will contribute to greater activities and better quality of life. Clearly, resistance to antimetabolites remains a formidable obstacle, but increasing opportunities for translational research, aimed at understanding the mechanisms by which this arises clinically, offers the prospect of improvements in this key area in the future.
